Savitr Capital

Glytec, LLC is a clinical information technology company specializing in insulin management and glycemic control solutions for diabetes patients globally. Established in 2006 and based in Waltham, Massachusetts, with an additional office in Greenville, South Carolina, Glytec develops the eGlycemic Management System (eGMS), a cloud-based decision support system designed to mitigate the risks and costs associated with hyperglycemia and hypoglycemia. The eGMS includes several key components: SmartClick for accessing patient applications from electronic medical records, GlucoSurveillance for real-time glycemic insights, Glucommander for personalized insulin dosing recommendations, and GlucoMetrics for performance analytics of glycemic control in hospital settings. Additionally, Glytec offers Hospital-to-Home Discharge Recommendations to assist with post-discharge insulin management. The company's patented and FDA-cleared solutions aim to enhance the safety and effectiveness of insulin therapy, ultimately helping patients achieve their treatment goals while reducing complications and healthcare costs. Glytec operates as a subsidiary of Aseko, Inc.

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, They have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of their pipeline.

Ancora Heart focuses on improving the lives of individuals suffering from heart failure through innovative medical solutions. The company has developed the AccuCinch System, an investigational therapy aimed at addressing the underlying causes of heart failure by repairing the enlarged left ventricle. This percutaneous ventricular restoration system is designed to alleviate symptoms such as extreme fatigue, difficulty breathing, and cognitive challenges. By reducing the size of the left ventricle and reinforcing the heart wall, Ancora Heart's treatment offers a minimally invasive option for patients who currently have limited alternatives. Through its advancements, Ancora Heart aims to enhance the quality of life and longevity for those affected by heart failure.

Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.

Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.